FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197746> ?p ?o ?g. }

• W3197746 endingPage "7622" @default.
• W3197746 startingPage "7622" @default.
• W3197746 abstract "7622 Background: ALD518 is a humanized anti-IL-6 antibody being developed for the treatment of anemia, cachexia, and fatigue. The primary objective of the study was to determine the efficacy and safety of ALD518. Methods: 124 patients (pts) with advanced NSCLC, ECOG 0-3, weight loss in the preceding 3 months of >5% body weight, hemoglobin >7g/dl and C-reactive protein (CRP) > 10 mg/L were dosed. Pts were randomized to 1 of 4 treatment groups (∼30/group). Placebo or ALD518 80 mg, 160 mg, or 320 mg was administered i.v. every 8 weeks. Pts were followed up for 24 weeks. Data included FACIT-F, FACT-L, body composition (DEXA), lab safety tests (LSTs) and adverse events (AEs). Results: 29 pts completed the study, 52 died of progressive disease, 5 withdrew because of AEs, and 38 failed to complete every visit. There were no DLTs or infusion reactions. 84 pts had serious AEs of which 1 was deemed possibly related to administration of ALD518 (rectal hemorrhage). Enough patients remained in the study up to week 12 to make a statistical comparison valid. The mean (±SD) values for lean body mass (LBM), FACT-L lung symptom subscale (LCS) and FACIT-F fatigue subscale (FS) are shown in the Table. Conclusions: ALD518 given to pts with NSCLC was safe and well tolerated. ALD518 improved the lung symptom score, reversed fatigue, and there was less loss of LBM (-0.19 kg on ALD518 vs. -1.50 kg on placebo). There were no major safety signals or infusion reactions related to the administration of ALD518. Visit n LBM (kg) n FACT-LLCS n FACIT-FFS ALD518 Pre-dose 93 41.90 (±9.35) 93 13.3 (±4.3) 93 20.5 (±9.6) (pooled) Week 2 - - 79 15.1 (±3.8)* 79 22.9 (±10.5)** Week 12 35 41.71 (±10.29) 39 15.6 (±5.2) 39 23.8 (±10.9) Placebo Pre-dose 31 41.58 (±10.74) 31 13.7 (±3.4) 31 21.9 (±9.6) Week 2 - - 29 14.1 (±4.2) 29 21.3 (±11.1) Week 12 20 40.08 (±11.00) 21 15.2 (±3.9) 21 22.1 (±13.2) * p ≤ 0.0006. ** p = 0.025 (paired t-test compared to baseline). Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Alder Biopharmaceuticals Inc. Alder Biopharmaceuticals Inc. Alder Biopharmaceuticals Inc." @default.
• W3197746 created "2016-06-24" @default.
• W3197746 creator A5020397680 @default.
• W3197746 creator A5027105537 @default.
• W3197746 creator A5039406215 @default.
• W3197746 creator A5058183811 @default.
• W3197746 creator A5070977545 @default.
• W3197746 creator A5076954449 @default.
• W3197746 date "2010-05-20" @default.
• W3197746 modified "2023-10-18" @default.
• W3197746 title "Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial." @default.
• W3197746 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7622" @default.
• W3197746 hasPublicationYear "2010" @default.
• W3197746 type Work @default.
• W3197746 sameAs 3197746 @default.
• W3197746 citedByCount "35" @default.
• W3197746 countsByYear W31977462012 @default.
• W3197746 countsByYear W31977462013 @default.
• W3197746 countsByYear W31977462014 @default.
• W3197746 countsByYear W31977462016 @default.
• W3197746 countsByYear W31977462017 @default.
• W3197746 countsByYear W31977462018 @default.
• W3197746 countsByYear W31977462019 @default.
• W3197746 countsByYear W31977462020 @default.
• W3197746 countsByYear W31977462021 @default.
• W3197746 countsByYear W31977462022 @default.
• W3197746 countsByYear W31977462023 @default.
• W3197746 crossrefType "journal-article" @default.
• W3197746 hasAuthorship W3197746A5020397680 @default.
• W3197746 hasAuthorship W3197746A5027105537 @default.
• W3197746 hasAuthorship W3197746A5039406215 @default.
• W3197746 hasAuthorship W3197746A5058183811 @default.
• W3197746 hasAuthorship W3197746A5070977545 @default.
• W3197746 hasAuthorship W3197746A5076954449 @default.
• W3197746 hasConcept C120863210 @default.
• W3197746 hasConcept C121608353 @default.
• W3197746 hasConcept C126322002 @default.
• W3197746 hasConcept C141071460 @default.
• W3197746 hasConcept C142724271 @default.
• W3197746 hasConcept C147583825 @default.
• W3197746 hasConcept C168563851 @default.
• W3197746 hasConcept C197934379 @default.
• W3197746 hasConcept C204787440 @default.
• W3197746 hasConcept C27081682 @default.
• W3197746 hasConcept C2776256026 @default.
• W3197746 hasConcept C2777704314 @default.
• W3197746 hasConcept C2778248108 @default.
• W3197746 hasConcept C2779177807 @default.
• W3197746 hasConcept C511355011 @default.
• W3197746 hasConcept C544821477 @default.
• W3197746 hasConcept C71924100 @default.
• W3197746 hasConcept C81729549 @default.
• W3197746 hasConcept C90924648 @default.
• W3197746 hasConceptScore W3197746C120863210 @default.
• W3197746 hasConceptScore W3197746C121608353 @default.
• W3197746 hasConceptScore W3197746C126322002 @default.
• W3197746 hasConceptScore W3197746C141071460 @default.
• W3197746 hasConceptScore W3197746C142724271 @default.
• W3197746 hasConceptScore W3197746C147583825 @default.
• W3197746 hasConceptScore W3197746C168563851 @default.
• W3197746 hasConceptScore W3197746C197934379 @default.
• W3197746 hasConceptScore W3197746C204787440 @default.
• W3197746 hasConceptScore W3197746C27081682 @default.
• W3197746 hasConceptScore W3197746C2776256026 @default.
• W3197746 hasConceptScore W3197746C2777704314 @default.
• W3197746 hasConceptScore W3197746C2778248108 @default.
• W3197746 hasConceptScore W3197746C2779177807 @default.
• W3197746 hasConceptScore W3197746C511355011 @default.
• W3197746 hasConceptScore W3197746C544821477 @default.
• W3197746 hasConceptScore W3197746C71924100 @default.
• W3197746 hasConceptScore W3197746C81729549 @default.
• W3197746 hasConceptScore W3197746C90924648 @default.
• W3197746 hasIssue "15_suppl" @default.
• W3197746 hasLocation W31977461 @default.
• W3197746 hasOpenAccess W3197746 @default.
• W3197746 hasPrimaryLocation W31977461 @default.
• W3197746 hasRelatedWork W1750391852 @default.
• W3197746 hasRelatedWork W2057033568 @default.
• W3197746 hasRelatedWork W2078332276 @default.
• W3197746 hasRelatedWork W2111343721 @default.
• W3197746 hasRelatedWork W2147606462 @default.
• W3197746 hasRelatedWork W2404327516 @default.
• W3197746 hasRelatedWork W2799199880 @default.
• W3197746 hasRelatedWork W2892039131 @default.
• W3197746 hasRelatedWork W3144674925 @default.
• W3197746 hasRelatedWork W2612605095 @default.
• W3197746 hasVolume "28" @default.
• W3197746 isParatext "false" @default.
• W3197746 isRetracted "false" @default.
• W3197746 magId "3197746" @default.
• W3197746 workType "article" @default.